Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/Ib Study of Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

NCT04085315 is registered in ClinicalTrials.gov with Collin Blakely as lead sponsor.

NCT NCT04085315
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04085315 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/Ib Study of Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Lead sponsor
Collin Blakely
Phase
Phase 1
Overall status
Completed
Start date
November 12, 2019
Completion date
October 20, 2025
Enrollment
23 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

egfr gene mutation, lung cancer metastatic